Protagonist Therapeutics Inc
PTGX
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.2B
Close$
$-3.79
102.7% downside
Current Fair Value
102.7% downsideOvervalued by 102.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $9.20 Billion |
|---|---|
| Enterprise Value | $8.80 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.05 |
| Beta | 1.79 |
| Outstanding Shares | 65,935,769 |
Return
| Return on Equity | 9.85% |
|---|---|
| Return on Assets | 9.36% |
| Return on Invested Capital | 8.36% |
Valuation & Multiples
| P/E Ratio | 117.4 |
|---|---|
| PEG | -20.66 |
| Price to Sales | 46.23 |
| Price to Book Ratio | 11.56 |
| Enterprise Value to Revenue | 38.03 |
| Enterprise Value to EBIT | 124.02 |
| Enterprise Value to Net Income | 106 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$2.23
Average shareholder expectationRevenue Estimate
$202.70 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$2.43
Average shareholder expectationRevenue Estimate
$240.13 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.5935▲ 36.00% |
|---|---|
| Total Calls | 396,100▲ 36.63% |
| Total Puts | 235,100▲ 247.27% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 115.84%▼ 5.17% |
|---|---|
| Total Invested | $9.36B▲ 12.82% |
| Investors Holding | 358▲ 24.00% |
ESG Score
No data